ENZON PHARMACEUTICALS INC
ENZN
ENZN was delisted on the 19th of May, 2016.
79 hedge funds and large institutions have $34.2M invested in ENZON PHARMACEUTICALS INC in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 16 closing their positions.
4% less funds holding
Funds holding: 82 → 79 (-3)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
39% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 33
40% less capital invested
Capital invested by funds: $57.1M → $34.2M (-$22.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$487K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$376K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$309K |
| 4 |
Goldman Sachs
New York
|
+$268K |
| 5 |
State Street
Boston,
Massachusetts
|
+$238K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$5.16M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$793K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$427K |
| 4 |
HMC
Harbert Management Corporation
Birmingham,
Alabama
|
-$406K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$368K |
ENZN Hedge Fund Activity: Q4 2013 in Review
79 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q4 2013, worth a combined $34.2M — down 40% from $57.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ENZN and 13 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 20 added.
The largest buyer was Pictet Asset Management (UK), opening a new position worth an estimated $487K. The largest seller was Baupost Group, cutting an estimated $5.16M.
- 79 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q4 2013, down from 82 in Q3 2013.
- Funds reported $34.2M of ENZON PHARMACEUTICALS INC stock for Q4 2013, down 40% quarter-over-quarter.
- 13 funds opened new ENZON PHARMACEUTICALS INC positions in Q4 2013 and 16 closed out, a net change of -3 holders.
- The largest ENZON PHARMACEUTICALS INC buyer in Q4 2013 was Pictet Asset Management (UK), an estimated $487K added.
- The largest ENZON PHARMACEUTICALS INC seller in Q4 2013 was Baupost Group, an estimated $5.16M sold.
Based on aggregated 13F filings for Q4 2013.